灵芝多糖对肿瘤细胞与内皮细胞相互作用的影响

目的:研究灵芝多糖对肿瘤细胞与内皮细胞相互作用的影响。方法:应用免疫荧光法配合使用显微镜将内皮细胞区分出来后,通过MTT法观察灵芝多糖在内皮细胞增殖分化过程中的作用,并使用相同的方法观察肿瘤细胞的增殖分化过程与灵芝多糖的关系,同时观察灵芝多糖是否干扰2种细胞间产生的黏附作用及迁移反应。结果:内皮细胞的增殖分化过程与灵芝多糖不存在明显联系,肿瘤细胞的增殖分化过程与灵芝多糖也不存在明显联系,即无明显的细胞毒性反应。但灵芝多糖可阻碍2种细胞间产生的黏附作用和迁移反应,减少肿瘤细胞的迁移百分比。结论:灵芝多糖具有抗肿瘤功效,其作用机制为阻碍肿瘤细胞的黏附作用和迁移反应。     

亚砷酸钠对人脐静脉内皮细胞迁移、增殖的影响及其机制

目的 探讨亚砷酸钠对体外培养的人脐静脉内皮细胞(HUVECs)迁移和增殖的影响.方法 通过细胞损伤修复实验和细胞增殖实验分别观察亚砷酸钠对细胞迁移、增殖能力的影响.RT-PCR分析其mRNA表达.结果 亚砷酸钠抑制HUVECs迁移和增殖能力,两者均呈典型的剂量效应关系.并发现亚砷酸钠下调HUVECs的黏着斑激酶(FAK)和原癌基因蛋白(c-Myc)的mRNA水平.结论 亚砷酸钠通过下调FAK和c-Myc基因表达抑制细胞迁移和增殖能力,提示其在损伤血管内皮细胞修复机能中起重要作用.     

鳄鱼血多糖抗肿瘤作用研究

目的:鳄鱼血抗肿瘤活性成分分离及其抗肿瘤作用研究。方法:从鳄鱼血中分离提取出3种多糖成分,分别对其进行肺癌细胞、肝癌细胞和乳腺癌细胞的毒性评价和抗迁移能力评价,利用MTT方法检测多糖成分对肿瘤细胞增殖的抑制率,并通过细胞迁移实验评价3种鳄鱼血多糖组分不同浓度对多种肿瘤细胞迁移能力的影响。结果:从鳄鱼血中分离提取的三种多糖成分ABPSⅠ、ABPSⅡ、ABPSⅢ,对于3类不同类型的恶性肿瘤细胞的增殖和迁移能力均具有一定的抑制作用。结论:鳄鱼血中的多糖成分能够较好的抑制肝癌、肺癌和乳腺癌肿瘤细胞的增殖和迁移。     

灰树花β多糖协同化疗药物抗肿瘤作用及其分子机理初探

目的探讨灰树花β多糖在抗肿瘤细胞中的作用和协同化疗药物增加其杀伤肿瘤细胞的作用。另外通过对p53和M DM 2的研究,发现了两者协同作用的分子机理。方法用CCK-8方法测定了灰树花β多糖协同化疗药物处理HCT 116后的细胞存活率(cell surv iva l rate,CSR);用PCR的方法测定了p53、M DM 2基因的表达。结果(1)灰树花β多糖对肿瘤细胞的直接杀伤作用高于灵芝多糖。(2)灰树花β多糖协同化疗药物增强其对肿瘤细胞的杀伤作用。(3)灰树花β多糖协同化疗药物的分子机理和抑制抑癌基因p53的拮抗物M DM 2基因的表达相关。结论灰树花β多糖具有直接杀伤肿瘤作用和化学药物协同抗肿瘤作用。     

淫羊藿苷通过Notch1/Jagged1信号通路抑制人前列腺癌细胞的增殖、迁移和侵袭

目的:探讨淫羊藿主要有效成分淫羊藿苷(icariin, ICA)对人前列腺癌细胞(prostate cancer cells, PC-3细胞)的侵袭、迁移和增殖的影响及作用机制。方法:运用不同浓度的ICA对PC-3细胞进行24,36,48 h的预处理后,采用MTT法筛选合适的受试浓度;采用流式细胞术检测ICA对PC-3细胞周期的影响;采用划痕实验和Transwell实验分别检测ICA对PC-3细胞的迁移能力和侵袭能力的影响;采用RT-PCR和Western blot分别检测ICA对PC-3细胞Notch1、Jagged1、Hes1、Hey1 mRNA及蛋白表达的调控作用。结果:不同浓度的ICA处理PC-3细胞24,36,48 h后,对PC-3细胞的增殖有明显抑制作用,且呈浓度和时间依赖性;流式细胞术检测结果表明ICA主要将PC-3阻滞在G0/G1期;划痕实验和Transwell实验结果显示ICA对PC-3细胞的迁移和侵袭能力有明显抑制作用;1×10^-4 mol·L^-1的ICA作用于PC-3细胞48 h后,对Notch1、Jagged1、Hes...     

沙蟾毒精抑制血管生成的作用

探讨沙蟾毒精(arenobufagin)对体内外血管生成的抑制作用。采用MTT法检测沙蟾毒精对人鼻咽癌细胞(CNE-2)、人喉癌细胞(Hep2)、人神经母细胞瘤(SH-SY5Y)、人结肠癌细胞(LOVO)、人前列腺癌细胞(PC-3及DU145)和人脐静脉内皮细胞(HUVECs)的细胞毒性及运用光学显微镜观察细胞形态的变化,发现沙蟾毒精剂量依赖性抑制CNE-2、Hep2、SH-SY5Y、LOVO、PC-3、DU145和HUVECs增殖,且在对人癌细胞亚细胞毒浓度下能够有效抑制HUVECs的增殖。采用鸡胚尿囊膜(chick embryo chorioallantoic membrane,CAM)模型观察新生血管的生成,结果发现沙蟾毒精作用24 h后,尿囊膜新生血管生成明显减少。采用细胞周期分析法观察到沙蟾毒精阻滞HUVECs于G2/M期,且随着浓度增加,细胞出现sub-G1凋亡峰。运用流式细胞术检测沙蟾毒精作用HUVECs后的凋亡现象以及线粒体膜电位的变化,确证沙蟾毒精呈时间和剂量依赖性诱导HUVECs凋亡,同时检测到线粒体膜电位下降。Western blotting检测发现,沙蟾毒精作用HUVECs后,凋亡标志...     

枸杞多糖对人前列腺癌PC-3细胞凋亡的影响

目的研究枸杞多糖(LBP)对人前列腺癌PC-3细胞凋亡的影响。方法体外培养的人前列腺癌PC-3细胞经枸(LBP)处理后,采用MTT法测定细胞的增殖情况,流式细胞仪分析LBP对PC-3细胞周期和凋亡的影响,TUNEL法观察PC-3细胞凋亡的变化,用免疫组化法检测其Bcl-2和Bax蛋白的表达。结果LBP可明显抑制人前列腺癌PC-3细胞的生长,并能诱导PC-3细胞凋亡,凋亡率分别为8.5%、17.5%、29.5%、37.5%和41.5%,与对照组比较,差异有非常显著性(P<0.01);同时PC-3细胞Bcl-2/Bax蛋白比值显著下降,呈明显的剂量-效应关系。结论LBP对人前列腺癌PC-3细胞DNA具有损伤作用,能诱导PC-3细胞的凋亡,调节其相关基因的表达。     

普纳替尼对人血管内皮细胞功能的影响

目的 观察普纳替尼(Ponatinib)对人血管内皮细胞的增殖、迁移、血管形成及NO合成释放的影响, 从细胞水平评价Ponatinib血栓不良反应形成机制。方法 采用CCK-8法、体外划痕法、Matrigel基底膜成管法及NO检测试剂盒分别考察Ponatinib对人脐静脉内皮细胞(HUVECs)的细胞毒作用、迁移能力、血管形成能力及细胞NO释放水平的影响。结果 研究表明Ponatinib对HUVECs细胞半数抑制浓度(IC₅₀)为(0.69±0.05)μmol/L。非毒性剂量的Ponatinib能够不同程度抑制HUVECs细胞的迁移、血管形成及NO的释放(P<0.05)。结论 Ponatinib通过影响人血管内皮细胞增殖、迁移、血管形成等正常功能而造成血管内皮损伤, 可能为其诱发血栓的原因之一。     

EGCG 对HepG2 肝癌细胞跨内皮迁移的影响及机制研究

目的探讨表没食子儿茶素没食子酸酯(EGCG)对体外培养的人肝癌细胞系HepG2细胞跨内皮迁移的影响及其机制。方法采用癌细胞与内皮细胞的单层粘附实验检测HepG2细胞与内皮细胞的粘附;利用Transwell小室法分析HepG2细胞的跨内皮迁移;运用real time PCR检测LOX-1mRNA水平,Western Blot分析LOX-1蛋白的表达。结果 EGCG(5,10,20μM)能够浓度依赖性地抑制TNF-α(50ng·mL-1)所诱导的HepG2细胞与内皮细胞的粘附、HepG2细胞的跨内皮迁移以及LOX-1mRNA和蛋白表达的上调。LOX-1中和抗体TS20(10ng·mL-1)也能抑制TNF-α对HepG2细胞的这些效应。结论 EGCG通过减少LOX-1的表达能明显抑制TNF-α诱导的肝癌细胞与内皮细胞的粘附及跨内皮迁移。LOX-1可能作为一种粘附分子,参与介导肝癌细胞与内皮细胞的相互作用。     

2-(N-丙基)-6-三氟甲氧基苯并噻唑抗肿瘤活性研究

目的研究2-(N-丙基)-6-三氟甲氧基苯并噻唑的抗肿瘤活性和机制。方法采用CCK-8法测定药物对HeLa、HepG2、MCF-7和SP2/0肿瘤细胞增殖的影响;Hoechst 33258染色和Annexin V-FITC/PI双染法,检测药物对MCF-7细胞的促凋亡作用,观察药物作用后肿瘤细胞的形态;采用细胞划痕实验,检测药物对肿瘤细胞迁移能力的影响。结果 2-(N-丙基)-6-三氟甲氧基苯并噻唑能明显抑制4种肿瘤细胞的增殖,且具有较好的选择性,特别是对MCF-7作用最明显,其IC_(50)值为(12.91±0.69)μmol·L~(-1)。对MCF-7细胞有比较强的抗迁移作用,划痕愈合率较对照组明显降低,还可诱导MCF-7细胞的早期凋亡。结论 2-(N-丙基)-6-三氟甲氧基苯并噻唑可抑制肿瘤细胞的增殖,并且通过诱导MCF-7细胞的早期凋亡,抑制MCF-7细胞迁移,从而发挥其增殖抑制作用。     

抗肿瘤多肽AP25体外活性研究

目的研究抗肿瘤多肽AP25的体外活性。方法通过MTT实验、细胞迁移实验、管状结构形成实验检测AP25体外活性。结果 AP25对HUVEC、MGC-803、HeLa、HCT116、MDA-MB-231细胞增殖均有明显的抑制作用,对HU-VEC细胞迁移和管状结构形成有明显的抑制作用。结论AP25主要通过抑制内皮细胞的增殖、迁移和管状结构形成,来抑制肿瘤新生血管的生成,进而发挥其抗肿瘤活性,同时AP25也具有直接抑制肿瘤细胞生长的活性。     

GLB prevents tumor metastasis of Lewis lung carcinoma by inhibiting tumor adhesion actions

AIM: To investigate the inhibitory effect of a new compound of GLB on tumor metastasis in vivo and analyze its actions on tumor cell adhesion to clarify its mechanism. METHODS: The effect of GLB on tumor metastasis was analyzed by Lewis lung carcinoma model. The pathological morphology of lung alveolar was evaluated by hematoxylin-eosin staining. The effect of GLB on the proliferation of human prostate cancer cell (PC-3M, with a high metastatic characteristic) was studied using the MTT method, and its actions on PC-3M cell adhesion to human umbilical vein endothelial cells (HUVEC) and laminin were analyzed in vitro. RESULTS: GLB (100 mg/kg/d for 28 d, ig) reduced the number of lung colonies of Lewis lung carcinoma metastasis significantly (P<0.05). Simultaneously, GLB could mitigate the damage of lung alveolar caused by metastasic tumor deposits. In vitro, GLB inhibited dramatically the adhesion of PC-3M cells to HUVEC (P< 0.01) and laminin (P<0.05), without cytotoxic or anti-proliferative action on PC-3M cells. CONCLUSION: GLB has anti-tumor metastatic activity, which partly depends on its inhibition of tumor adhesion.     

Three previously undescribed steroidal glycoalkaloids from Solanum lyratum and their anti-tumor activities

In the present study, three previously undescribed steroidal glycoalkaloids (compounds 1–3) were isolated from Solanum lyratum. Their structures were elucidated based on comprehensive spectroscopic data. Their anti-angiogenesis and anti-metastatic activities were evaluated by MTT and wound-healing assays, respectively. Tumor-derived vascular endothelial cells (TdECs), obtained by co-culture of A549 and human umbilical vein endothelial cells (HUVECs), were treated with compounds 1–3. Results showed that compounds 1–3 significantly inhibited the migration of TdECs at 25 μM despite the weak cytotoxic activities, which indicated that the compounds exerted anti-tumor activities by inhibiting metastasis, rather than directly inhibiting the proliferation of TdECs.     

新型蛋白酶体抑制剂 YSY-01A诱导PC-3M细胞自噬的作用

在前期研究中,YSY-01A通过抑制蛋白酶体活性,对多种肿瘤细胞表现出增殖抑制作用。但是,YSY-01A对于与蛋白酶体途径有着密切联系的自噬系统的影响目前还不清楚。本文研究目的是探讨YsY-01A对自噬的影响与分子机制。研究结果表明,YSY-01A能够显著抑制PC-3M细胞的增殖（P〈0．001,IC50=287 nM,48h）,并且该抑制作用具有时间依赖性与浓度依赖性。YSY-01A（400nM）能够在短时间内诱导PC．3M细胞自噬,12h后自噬活动步入末期。分子实验结果表明,YSY-01A能够明显促进P53蛋白的磷酸化、抑制mTOR的活化,上调Beclin-1与LC3的表达。而在抑制自噬后,可增加JPC-3M细胞对YSY．01A的敏感性。总之,YSY-01A可抑Nec-3M细胞增殖,并能够诱导PC-3M细胞自噬,自噬在12h后步入末期,抑制自噬后,可增强YSY-01A对PC-3M细胞的增殖抑制作用。     

Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the RhoA/ROCK/NLRP3 pathway

Prostate cancer is a male malignant tumor disease with high incidence and mortality. This study was designed to explore the effects of ulinastatin (UTI) on the malignant progression of prostate cancer and its relevant mechanism of action. Human prostate cancer cell line PC-3 was applied to investigate the anticancer activity of UTI. PC-3 cells were treated with increasing concentrations (400, 800, and 1600 U/ml) of UTI. Cell proliferation, migration, invasion, and apoptosis were determined by cell counting kit-8 (CCK-8), colony formation, wound-healing, Transwell assay, and flow cytometry analysis, respectively. The expression level of corresponding proteins was detected by western blot. In addition, PC-3 cells were pretreated with RhoA agonist CN03 (1 μg/ml) or NLRP3 agonist nigericin (10 μM) before UTI treatment, and the cellular behaviors above were detected again. It was demonstrated that UTI significantly suppressed cell proliferation, migration, and invasion but promoted apoptosis in PC-3 cells in a concentration-dependent manner. Meanwhile, UTI could block RhoA/ROCK/NLRP3 inflammasome pathway in PC-3 cells, and the activation of RhoA or NLRP3 inflammasome partly weakened the impacts of UTI on cell proliferation, migration, and apoptosis in PC-3 cells, respectively. In summary, our study demonstrated the antitumor activity of UTI against prostate cancer by regulating RhoA/NLRP3 inflammasome pathway, providing a promising candidate drug for the therapeutic treatment of prostate cancer.     

Anti-angiogenic activity and intracellular distribution of epigallocatechin-3-gallate analogs

Angiogenesis, a process of construction of new blood capillaries, is crucial for tumor progression and metastasis. Our previous studies demonstrated that a component of green tea, epigallocatechin-3-gallate (EGCG), suppressed angiogenesis and subsequent tumor growth. In this study, to elucidate the detailed mechanism of the anti-angiogenic effect of EGCG and to enhance the antiangiogenic activity of EGCG, we designed and synthesized EGCG derivatives and examined their biological effect and intracellular localization in human umbilical vein endothelial cells (HUVECs). EGCG derivatives aminopentyl dideoxyEGCG and aminopentyl dideoxygallocatechin-3-gallate (cis-APDOEGCG and trans-APDOEGCG) had an enhanced inhibitory effect on the proliferation when used at more than 30 μM. To elucidate antiangiogenic effect of EGCG, we used a 1 μM concentration for subsequent experiments where no effect on proliferation was observed. These EGCG derivatives showed a stronger inhibitory effect on migration, invasion, and tube formation by HUVECs than the non-derivatized EGCG. Furthermore, the derivatives induced a change in the distribution of F-actin and subsequent morphology of the HUVECs. Next, we synthesized fluorescent TokyoGreen-conjugated EGCG derivative (EGCG-TG) and observed the distribution in HUVECs under a confocal laser scanning microscope. Abundant fluorescence was observed in the cells after a 3-h incubation, and was localized in mitochondria as well as in cytoplasm. These results suggest that EGCG was incorporated into the HUVECs, that a portion of it entered into their mitochondria.     

TFAR19蛋白协同米非司酮对前列腺癌PC-3M细胞凋亡的影响

目的初步探讨TFAR19协同米非司酮(MIF)对前列腺癌PC-3M细胞凋亡的影响。方法构建TFAR19真核表达载体,用脂质体介导的方法转染PC-3M细胞。MTT法检测5、10、20、50和100μmol·L-1MIF作用于前列腺癌PC-3M细胞24~96h的吸光度(A)值。在转染TFAR19的细胞中加入20mol·L-1MIF培养24、48h,MTT比色法检测细胞增殖,原位末端标记(TUNEL)法检测细胞凋亡率,透射电镜进一步观察细胞超微结构的改变。结果构建了PCI-neo-TFAR19真核表达载体并在转染的PC-3M细胞中得到了瞬时表达。MTT实验表明,与对照组相比,5、10μmol·L-1MIF组的A值差异无统计学意义(P>0.05),20、50和100μmol·L-1MIF组的A值差异有统计学意义(P<0.01),MIF对前列腺癌PC-3M细胞的抑制作用呈时间、剂量依赖性;转染PCI-neo-TFAR19并加入20 mol·L-1MIF后,与对照组及单独应用MIF组相比,细胞生长明显受到抑制(P<0.01),细胞凋亡率明显增加(P<0.01),透射电镜观察到典型的细胞凋亡特征(细胞体积缩小,核皱缩、碎裂,染色质呈块状边集等)。结论TFAR19蛋白能够协同米非司酮促进前列腺癌PC-3M细胞凋亡,有望成为前列腺癌的辅助治疗药物。     

Effect of nicotine on human umbilical vein endothelial cells (HUVECs) migration and angiogenesis

The effects of nicotine on vascular endothelial cells have not been completely elucidated. We performed this study to assess the changes in cellular behaviors of human umbilical vein endothelial cells (HUVECs) treated with nicotine. We examined changes in cell count and morphology and assayed cellular migration with Boyden chamber and microcapillary tube formation in a Matrigel matrix following treatment with various concentrations of nicotine. Compared to the control, nicotine stimulated cell proliferation, migration, and tube formation at concentrations similar to those found in smokers. Although there were no specific morphological changes in HUVECs treated with nicotine at the concentration similar to that in smokers, at high concentration (10(-4) M), morphological changes such as cytoplasmic vacuolization and irregular cell shape were observed, which were assumed to be the result of direct cytotoxicity of nicotine. In HUVECs, nicotine enhanced cellular proliferation, migration and angiogenesis in vitro, and thus caused a functional change, not a morphological change at a concentration similar to that in habitual smokers.     

靶向KDR siRNA与5-氟尿嘧啶对PC3细胞增殖的协同抑制

目的研究以KDR为靶标的小干扰RNA(siRNA)与化疗药5-氟尿嘧啶(5-FU)联合应用抑制PC3细胞增殖的作用。方法已构建了Psilencer3.1-KDR siRNA表达载体,采用脂质体介导的基因法转染PC3细胞,MTT法检测细胞生长速度的变化和流式细胞仪检测细胞周期的变化,以未转染和转染阴性对照质粒pSilencer3.1-NC的PC3细胞为对照,MTT法检测细胞在含5-FU[(0～1.56×106)nmol/L]的培养液中48h后的生存率,并计算IC50。结果转染pSilencer3.1-KDR后PC3细胞生长速度明显变慢,PC3细胞的G0/G1期百分率明显增高,而S期和G2、M期的细胞减少,与其余组相比具有统计学差异(P<0.01)。MTT结果显示,pSilencer3.1-KDR细胞组5-FU的IC50,为(898.34±44.34)nmol/L(P<0.01)。结论 KDRsiRNA与5-FU联用,可显著增强对PC3细胞增殖的抑制,提高肿瘤细胞对化疗药物的敏感性。